Novo Nordisk: Value Trap or Value Investment?

Key Takeaways

• CagriSema missed primary endpoint, shares fell 16%
• US price caps forced Novo to cut Ozempic price near €150
• 2026 guidance predicts 5‑13% revenue decline, ending growth streak
• Stock down 56% from 52‑week high, valuation halved
• Despite setbacks, Novo retains strong cash flow and pipeline

Pulse Analysis

Novo Nordisk rode a wave of unprecedented hype in 2024, with Ozempic and Wegovy turning obesity treatment into a cultural phenomenon. The company’s market cap briefly eclipsed $400 billion, and analysts likened its growth trajectory to that of Amazon, rewarding a price‑to‑earnings multiple in the mid‑30s. That exuberance was built on a pricing model that charged U.S. patients a premium far above European rates, fueling outsized margins and fueling investor optimism about a generational earnings engine.

The tide turned in early 2026 when CagriSema, touted as the next‑generation obesity drug, failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide in the REDEFINE 4 trial. The miss triggered a 16% intraday sell‑off and exposed the fragility of Novo’s pipeline‑driven valuation. Compounding the blow, a U.S. “Most Favored Nation” policy forced Ozempic prices down to roughly $150—close to European levels—stripping away a key source of cash flow. The company’s first‑ever revenue‑decline guidance, projecting a 5‑13% drop for 2026, cemented the market’s shift from growth‑stock enthusiasm to a more cautious stance.

Despite the setbacks, Novo Nordisk remains financially robust, boasting a strong balance sheet, sizable free cash flow, and a diversified portfolio that includes diabetes, hemophilia, and rare‑disease therapies. The company’s pipeline still contains promising candidates beyond obesity, and its global manufacturing footprint provides resilience against regional pricing shocks. Investors now weigh the trade‑off between short‑term valuation pain and the long‑term upside of a cash‑generating, research‑driven pharma giant. The key question is whether the current discount represents a temporary value trap or a permanent re‑rating in a more competitive, price‑sensitive market.